Please select the option that best describes you:

What dose/fractionation would you use for a patient with unresectable, ER+/PR+/HER2 negative breast cancer who declines chemotherapy and progresses locally after receiving endocrine therapy with abemaciclib?  

The patient has locally advanced disease with chest wall invasion and extensive axillary/IMN lymphadenopathy



Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more